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titis with allergic rhino bronchitis and
10.7% of atopic dermatitis with upper
respiratory diseases. Seventy ﬁve percent-
age patients were found to be primarily
allergic to mites, 7.1% to pollens, 10.7%
to cockroach and 7.1% to spores. Hundred
percentage patients reported that they took
the STRIPS regularly as directed by the
physician. 64.3% of the patients reported
their health improvement is good while
35.7% reported as very good. No adverse
events were reported by any of the
patients.
Conclusion: SLIT STRIP is found to be a
more convenient dosage form to be stored
at room temperature and in administering
sublingual strip especially in pediatric
patients over SLIT drops. Compliance and
adherence to the intake of STRIPS is good
and patient’s health improvement is also
good.
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ment, Coimbra, Portugal
Background: Although the efﬁcacy of spe-
ciﬁc immunotherapy (SIT) in allergic respi-
ratory disease is well established, its
application in atopic dermatitis has been a
controversial issue. The aim of this study
was to evaluate SIT efﬁciency in atopic
dermatitis.
Methods: We included 29 patients with
atopic dermatitis associated to house dust
mites, allergic bronchial asthma and/or rhi-
nitis. The severity of atopic dermatitis was
evaluated using SCORAD in the beginning
of the study (T0) and 1 year after the clini-
cal treatment (T1). All the patients were
controlled under medical treatment accord-
ing to the severity of the disease. Group I
included all patients submitted to SIT and
group II included those without SIT (con-
trol group).
Results: The 29 patients included in this
study (51.7% female, 48.3% male) had an
average age of 19.31 ± 8.8 years of age. In
these patients, the average SCORAD score
was 61.68 ± 35.5 and 41.62 ± 32.4 at T0
and T1, namely. The patients included in
group I and in group II had an average
age of 20.58 ± 6.9 and 16.9 ± 11.7 years,
respectively. SCORAD results (A - spread,
B - intensity, C - subjective signs) are pre-
sented in the below table.
Conclusion: We observed that all SCORAD
parameters improved after 1 year of SIT,
with statistical signiﬁcance (P < 0.05). Our
data suggests that SIT is an effective treat-
ment in patients with atopic dermatitis
associated to allergic respiratory disease.
341
Safety and tolerability of recombinant
Bet v 1 (rBet v 1) tablets in sublingual
immunotherapy (SLIT)
Winther, L1; Poulsen, L1; Robin, B2; Me´lac, M2; Malling, H1
1National University Hospital, Allergy Unit 4222, Copen-
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Background: Sublingual immunotherapy
(SLIT) using standardized, recombinant
allergen vaccines may enable a more repro-
ducible clinical response.
Methods: Two single-centre, randomized,
double-blind, placebo-controlled, parallel-
group, Phase I clinical studies investigated
the safety and tolerability of recombinant
Bet v 1 (rBet v 1) sublingual tablets in sub-
jects with birch pollen allergic rhinitis for
at least 2 years. The ﬁrst study investigated
higher doses of rBet v 1 SLIT (50–300 lg),
while the second investigated the 12.5–
100 lg range. Ten doses of SLIT (ﬁxed
dose or maximum reach by titration) or
placebo were administered. Safety and tol-
erability were assessed as well as physical
examination, vital signs, clinical laboratory
tests, 12-lead ECG and spirometry. Serum
IgE and IgG4 levels were measured.
Results: There were a total of 402 treatment
emergent adverse events (TEAEs) in 101 of
the 112 (90%) enrolled subjects. Three hun-
dred and twenty ﬁve TEAEs (81%) were
SLIT-related, with the most common being
oropharyngeal pruritus, ear pruritus, rhini-
tis and pharyngeal oedema. Fifty nine
percentage of TEAEs were mild and 3%
were severe. Ten SLIT subjects (12%) with-
drew due to TEAEs (all occurring after
administration of high doses between
50–300 lg). No serious AEs or deaths were
reported. Immunological assays showed an
increase in birch and/or Bet v 1 IgE titres in
69 out of 84 (82%) subjects and IgG4 titres
in 30 out of 84 (36%).
Conclusion: rBet v 1 sublingual tablets
were well tolerated up to a dose of 50 lg
without the need for dose titration. Further
studies are planned to identify the optimal
effective dose.
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Background: We have previously con-
structed a hypoallergenic candidate of the
major cat allergen Fel d 1 by duplicating
selected T-cell epitopes and disrupting
disulphide bonds. The hypoallergen,
recombinant (r) Fel d 1 (DTE III), showed
retained T cell reactivity and more than
1000 times reduced IgE-binding capacity
compared to unmodiﬁed rFel d 1. The aim
of this study was to evaluate rFel d 1
(DTE III) in our mouse model for cat
allergy.
Methods: BALB/c mice were subcutane-
ously (s.c.) sensitized with rFel d 1 on day
0, 14 and 28. Groups of sensitized mice
(n = 8–10) were therapeutically treated
(s.c.) with 50 or 200 lg rFel d 1 (DTE III),
50 lg rFel d 1 or PBS on day 30, 32 and
34, prior to intranasal allergen challenge
with cat dander extract (CDE) on day 39,
40 and 41. Airway hyperreactivity (AHR)
and immunoglobulin levels in serum were
analysed.
Results: Compared to PBS-treated/CDE-
challenged mice, the mice treated with
200 lg rFel d 1 (DTE III) showed a
reduced AHR to metacholine. Treatment
with 50 lg rFel d 1 (DTE III) or 50 lg
rFel d 1 did not result in a reduction in
AHR. Only four out of ten mice survived
treatment with 50 lg rFel d 1. Both
treatment with 50 and 200 lg rFel d 1
(DTE III), and with 50 lg rFel d 1 resulted
in a signiﬁcant increase in the serum levels
of rFel d 1-speciﬁc IgG1 and IgG2a, and a
signiﬁcant decrease of IgE compared to
PBS-treated/CDE-challenged mice. The dif-
ferences compared to PBS-treated/CDE-
challenged mice were most prominent for
the mice treated with 200 lg rFel d 1
(DTE III). This group of mice also had
lower levels of serum-IgE to rFel d 1 com-
pared to mice treated with 50 lg rFel d 1
(DTE III).
Conclusion: The rFel d 1 (DTE III) hypo-
allergen is a promising candidate for appli-
Table 1. For abstract 340.
N SCORAD A B C
T0 T1 P T0 T1 P T0 T1 P T0 T1 P
Group I
19 (65.5%) 64.67 ± 41.9 33.92 ± 33.5 0.001 37.13 ± 30.6 25.00 ± 30.7 0.005 11.16 ± 6.0 4.68 ± 5.1 0.002 9.58 ± 6.7 3.95 ± 4.7 0.005
Group II
10 (34.5%) 56.00 ± 18.7 56.25 ± 25.7 ns 29.00 ± 25.9 31.25 ± 25.0 ns 12.40 ± 4.8 12.20 ± 5.9 ns 6.80 ± 8.0 7.30 ± 8.8 ns
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